Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | MITF | O75030 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.39 |
| ▸ | PMM2 | O15305 | 1/20 | 0.39 |
| ▸ | MPI | P34949 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL405386 | 0.84 | TSHR (0.47) | MAPTTSHRKMT2AMEN1PARP1 | |
| SCHEMBL29742161 | 0.84 | TSHR (0.47) | MAPTTSHRKMT2AMEN1PARP1 | |
| SCHEMBL26199343 | 0.84 | MAPT (0.49) | MAPTTSHRCYP3A4KMT2AMEN1 | |
| SCHEMBL27747270 | 0.83 | PARP1 (0.50) | MAPTCYP3A4KMT2AMEN1PARP1 | |
| SCHEMBL1025814 | 0.82 | MAPT (0.48) | MAPTTSHRCYP3A4KMT2AMEN1 | |
| SCHEMBL2244805 | 0.82 | TDP1 (0.45) | MAPTTSHRKMT2AMEN1PARP1 | |
| SCHEMBL8195276 | 0.82 | MEN1 (0.38) | MAPTTSHRKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL358123 | 0.82 | EGFR (0.42) | MAPTTSHRKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL28027642 | 0.82 | MEN1 (0.38) | MAPTTSHRKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL2597703 | 0.82 | PARP1 (0.40) | MAPTTSHRKMT2AMEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10039753-B2 | Imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives as LRRK2 inhibitors | PFIZER INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-20170073343-A1 | Novel Imidazo[4,5-c]Quinoline And Imidazo[4,5-c][1,5]Naphthyridine Derivatives As LRRK2 Inhibitors | PFIZER INC. (US) | 2017-03-16 | — | — | US | disclosed |
| US-8895581-B2 | 1H-imidazo[4,5-c]quinolines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-25 | — | — | US | disclosed |
| US-8637670-B2 | Imidazo [4,5-C]quinoline derivatives and their use in the treatment of tumors and/or inflammation | Piramal Enterprises Limited (IN) | 2014-01-28 | — | — | US | disclosed |
| US-20130210832-A1 | 1H-IMIDAZO[4,5-C]QUINOLINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-15 | — | — | US | disclosed |
| EP-2448937-A1 | IMIDAZO [4,5-C]QUINOLINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF TUMORS AND/OR INFLAMMATION | Piramal Life Sciences Limited (IN) | 2012-05-09 | — | — | EP | disclosed |
| US-20120108627-A1 | IMIDAZO [4,5-C]QUINOLINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF TUMORS AND/OR INFLAMMATION | Piramal Enterprises Limited (IN) | 2012-05-03 | — | — | US | disclosed |
| WO-2011001212-A1 | IMIDAZO [4,5-C]QUINOLINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF TUMORS AND/OR INFLAMMATION | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-01-06 | — | — | WO | disclosed |
| WO-2010139747-A1 | 1H-IMIDAZO[4, 5-c]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170073343-A1 | Novel Imidazo[4,5-c]Quinoline And Imidazo[4,5-c][1,5]Naphthyridine Derivatives As LRRK2 Inhibitors | LRRK2, PARK7, SNCA | MAPT 285/4885TSHR 1893/4885CYP3A4 1897/4885 |
| US-10039753-B2 | Imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives as LRRK2 inhibitors | LRRK2, PARK7, SNCA | MAPT 246/4885TSHR 2155/4885CYP3A4 1617/4885 |
| US-20130210832-A1 | 1H-IMIDAZO[4,5-C]QUINOLINES | MKI67, CCNA1, CCNB1 | MAPT 4491/4885TSHR 2137/4885CYP3A4 430/4885 |
| US-20120108627-A1 | IMIDAZO [4,5-C]QUINOLINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF TUMORS AND/OR INFLAMMATION | IL6, RPS6KA6, MTOR | MAPT 3264/4885TSHR 3613/4885CYP3A4 1158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.